IPO - Nordicus Partners Corp
Form Type: CORRESP
Filing Date: 2024-12-26
Corporate Action: Ipo
Type: New
Accession Number: 000149315224052056
Filing Summary: Nordicus Partners Corporation requested the acceleration of the effectiveness of its Registration Statement on Form S-1 (File No. 333-283709). The Company aims for the registration statement to be declared effective on December 30, 2024, at 1:00 p.m. Eastern Time. The request is made in compliance with Rule 461 under the Securities Act of 1933, and the Company has provided contact information for any queries related to this request.
Document Link: View Document
Additional details:
Registration Statement Date: 2024-12-10
Requested Effective Date: 2024-12-30
Requested Effective Time: 13:00
Contact Person: Ernest M. Stern
Contact Phone: (301) 910-2030
Notify Person: Henrik Rouf
Form Type: S-1/A
Filing Date: 2024-12-23
Corporate Action: Ipo
Type: Update
Accession Number: 000149315224051214
Filing Summary: Nordicus Partners Corporation filed Amendment No. 1 to its Form S-1 Registration Statement with the SEC. This update responds to SEC requests regarding the shares of common stock being registered, ensuring they are fully paid and non-assessable. The filing highlights the company's intention to sell 16,190,911 shares, with current owners, including CEO Henrik Rouf, holding significant voting control over corporate decisions. The registration statement reflects a reverse stock split of 1-for-10 approved earlier in June 2024. Other disclosures include company history, market intention, risk factors, management insights, financial condition, and additional relevant details pertaining to the offering.
Document Link: View Document
Additional details:
Cik: 0001011060
Business Contact: Henrik Rouf, President and CEO
Address: 280 South Beverly Dr. Suite 505 Beverly Hills, CA 90212
Selling Shareholders: Reddington Partners LLC, AC Nordic ApS, Alteral Therapeutics ApS, GK Partners ApS
Market Symbol: NORD
Last Reported Sale Price: $2.76
Reverse Stock Split Ratio: 1:10
Registration Statement No: 333-283709
Comments
No comments yet. Be the first to comment!